U.S. safety regulators investigating GM’s Cruise robotaxis blocking traffic, causing collisions

U.S. safety regulators investigating GM’s Cruise robotaxis blocking traffic, causing collisions


A Cruise vehicle in San Francisco, California, on Wednesday Feb. 2, 2022.

David Paul Morris | Bloomberg | Getty Images

U.S. automotive safety officials have opened a formal probe into the autonomous driving system used by General Motors’ self-driving vehicle unit Cruise.

The National Highway Traffic Safety Administration said it has received complaints about the self-driving vehicles – retrofitted Chevrolet Bolt EVs – engaging in “inappropriately hard braking” or becoming “immobilized while operating,” according to a filing.

Officials said although the two types of incidents appear to be separate from one another, they each result in the Cruise vehicles becoming unexpected roadway obstacles.

“This may introduce multiple potential hazards such as a collision with a Cruise vehicle, risk to a stranded passenger exiting an immobilized Cruise vehicle, or obstruction of other traffic including emergency vehicles,” NHTSA said in the filing.

Drew Pusateri, a spokesman for Cruise, a majority-owned unit of GM, said the San Francisco-based company has and will continue “to fully cooperate with NHTSA or any regulator.”

Pusateri said in an email that there’s “always a balance between healthy regulatory scrutiny and the innovation we desperately need to save lives.” He said the company has driven nearly 700,000 fully autonomous miles in an “extremely complex urban environment with zero life-threatening injuries or fatalities.”

The probe involves about 240 of the vehicles equipped with the software system, according to NHTSA. Each of the crash incidents had already been reported, as mandated by regulations involving self-driving vehicles.

The investigation, which was opened earlier this week, comes as Cruise awaits regulatory approval to expand its robotaxi service in San Francisco from about 30% of the city to the entire municipality.

NHTSA said it has received multiple reports of both incidents, including three instances of hard braking that resulted in the car being struck from behind. The safety agency said the specific number of the vehicles that have become immobilized on the road is unknown, however such incidents have been confirmed by the company and reported by media outlets.

NHTSA said the Office of Defects Investigation will determine “the scope and severity of the potential problem and fully assess the potential safety-related issues posed by these two types of incidents.”



Source

Ticketmaster parent Live Nation reaches settlement with Department of Justice over antitrust concerns
Business

Ticketmaster parent Live Nation reaches settlement with Department of Justice over antitrust concerns

Signs are seen at the Live Nation NYC headquarters on May 23, 2024 in New York City.  Michael M. Santiago | Getty Images Live Nation Entertainment has reached a settlement with the Department of Justice over antitrust concerns surrounding its Ticketmaster platform, a senior DOJ official said Monday. The settlement would see Ticketmaster unwind some […]

Read More
Inside the booming business of wellness third spaces and membership clubs
Business

Inside the booming business of wellness third spaces and membership clubs

A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: […]

Read More
FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More